Click here for slides on this topic


GLP-1

Abbreviation for glucagon-like peptide-1.


The following content matched the glossary term: GLP-1

No Increased Risk of Pancreatic Cancer With Incretins

Top

Data presented at EASD 2015 show no causal association between the use of incretin based therapies—DPP-4 inhibitors and GLP-1 receptor agonists—and pancreatitis or pancreatic cancer

NDEI.org Expert Commentary Vivian Fonseca MD on Results of ELIXA the First Cardiovascular Safety Study to Report Outcomes With A GLP-1 Receptor Agonist

Top

In this diabetes expert blog, Vivian Fonseca, MD, provides insights on results of the ELIXA cardiovascular safety study of the novel (at time of publishing) GLP-1 receptor agonist, lixisenatide.

ADA 2016 Older Adults

Top

Recommendations for older adults with diabetes from the 2016 ADA guidelines

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Top

Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-124. DURATION (Diabetes Therapy Utilization: Researching Changes in A1C, Weight, and Other Factors Through Intervention with Exenatide Once-Weekly) is a series of multinational studies comparing once-weekly exenatide with other antihyperglycemic therapies for treatment of type 2 diabetes.

Clinical Insights in Diabetes Newsletter November 2012

Top

Clinical Insights® in Diabetes Newsletter November 2012.

Statins and diabetes, Roux-en-Y for type 2 diabetes and obesity, sitagliptin or liraglutide for type 2 diabetes treatment, obesity and mortality, and DPP-4 inhibitors and cardiovascular disease.

Efficacy & safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 wks in metformin-treated patients

Top

Pratley RE, Nauck MA, Bailey T, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35(10):1986-1993. In 2011, Pratley and colleagues reported 52-week data from a trial that explored treatment with the DPP-4 inhibitor, sitagliptin, and the GLP-1 receptor agonist, liraglutide, among subjects with type 2 diabetes and A1C 7.5%–10%.

Clinical Insights in Diabetes Newsletter September 2012

Top

Clinical Insights® in Diabetes newsletter September 2012.

Intensive therapy in ACCORD-BP, Roux-en-Y gastric bypass for type 2 diabetes and obesity, diabetes and CVD mortality, and linagliptin and glimepiride for diabetes treatment.

ADA/European Association for the Study of Diabetes (EASD) Position Statement on Hyperglycemia Management in Type 2 Diabetes

Top

Joint position statement from ADA/EASD with clinical practice recommendations for managing hyperglycemia in type 2 diabetes

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes

Top

Horowitz M, Flint A, Jones KL, et al. Effect of the once daily human GLP 1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012 Mar 23. Epub ahead of print. Liraglutide reduces bodyweight in patients with type 2 diabetes mellitus (T2DM). This study aimed to investigate the mechanisms underlying this effect.

Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction

Top

Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes. 2011 Oct 17. [Epub ahead of print] AIMS: To evaluate the effects of adding glucagon-like peptide-1 (GLP-1) analogue therapy to insulin on glycated hemoglobin (HbA1c), weight, insulin dosage, treatment satisfaction, and risk of hypoglycaemia.

1 2 Next 

Slide Library Results

Search Results for: GLP-1 Slides Found: 93
Exenatide: Clinical Pharmacology
Exenatide: Effects on Glycemic Control in Combination With Current Oral Therapies
Exenatide: Proportion of Patients Achieving A1C <=7%
Glucagon-Like Peptide-1
Insulin and GLP-1 Responses to Meals
GLP-1 Release Is Reduced in Type 2 Diabetes
Effect of GLP-1 on the Beta-Cell
GLP-1 Infusion Improves Beta-Cell Insulin Secretion
GLP-1 and First-Phase Insulin Secretion
Exenatide: Effect on the Beta-Cell
Single Doses of Sitagliptin Increase Incretin Levels Over 24 Hours
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Body Weight
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Lipids
Frequent Adverse Events in Diabetic Patients Treated With GLP-1 Analogues
Frequent Adverse Events in Diabetic Patients Treated With DPP-4 Inhibitors
Change in A1C for GLP-1 Analogues vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults (cont)
Suitability of DPP-4 Inhibitors for Elderly Patients With Type 2 Diabetes
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: A1C
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: Body Weight
Once-Weekly Exenatide LAR vs Twice-Daily Exenatide for Type 2 Diabetes: A1C Categories
Fasting Levels of Intact GIP and GLP-1 Concentrations and DPP-4 Activity in Patients With Diabetes
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Design
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Results
Effect of Liraglutide and Insulin on Cardiovascular Disease Risk Factors
Liraglutide Effect on Cardiovascular Disease: Results Among Patients Switched from Exenatide
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Design
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Design
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Results
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Additional Results
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Change in A1C from Baseline
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Adverse Events and All-Cause Mortality
Switching from Sitagliptin to Liraglutide After 52 Weeks of Treatment: Design
Switching from Sitagliptin to Liraglutide After 52 Weeks of Treatment: 26-Week Extension Results for A1C Reduction
Liraglutide Treatment for 78 Weeks: Reductions in A1C from Baseline
DURATION-6: Design
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Background
GLP-1 Receptor Agonists: Dosage Adjustment by Degree of Renal Impairment
EXAMINE: No Increase in CV Events with Alogliptin Primary Endpoint
EXAMINE: No Increase in CV Events with Alogliptin Secondary Endpoint
EXAMINE: Significantly Greater A1C Change from Baseline with Alogliptin Vs Placebo
EXAMINE: Adverse Events
EXAMINE: Design
ADA Nutrition Guidelines: Priorities for Nutrition Management By Medication
LEAD-3: Liraglutide vs Glimepiride: A1C Level
LEAD-3: Liraglutide vs Glimepiride in Drug-Naïve Patients: A1C
LEAD-3: Liraglutide vs Glimepiride in Previously on Oral Agents: A1
US Trends in Type 2 Diabetes Treatment, 1997-2012: Type of Treatment Used, Visit with 2+ Compounds in 2012
US Trends in Type 2 Diabetes Treatment, 1997-2012: Medication Classes
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes | NDEI
Incretins Pancreatitis Risk Sulfonylureas Type 2 Diabetes Use Duration | NDEI
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes Gender | NDEI
Incretin Therapies Vs Sulfonylureas Pancreatitis Type 2 Diabetes | NDEI
IDF 2012 Type 2 Diabetes Guidelines Glucose Treatment Management | NDEI
IDF Type 2 Diabetes Treatment Guidelines Older Adults Elderly | NDEI
HARMONY 3 Albiglutide A1C Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide FPG Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide DPP-4 Inhibitor Weight Loss Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide DPP-4 Inhibitor Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide Type 2 Diabetes Metformin | NDEI
DPP-4 Inhibitors Type 2 Diabetes Treatment | NDEI
GLP-1 Receptor Agonists Type 2 Diabetes Treatment | NDEI
GLP-1 Receptor Agonists A1C Type 2 Diabetes | NDEI
HARMONY 3 DPP-4 Inhibitors Safety Pancreatitis | NDEI
Risk of Acute Pancreatitis Rare in Incretin-Treated Type 2 Diabetes | NDEI
Noninsulin Therapies ADA Type 1 Diabetes Guidelines | NDEI Slides
Hypoglycemia Management ADA Type 1 Diabetes Guidelines | NDEI
ADA EASD Treatment Algorithm Type 2 Diabetes | NDEI
DURATION-3 & LEAD-5 Post-Hoc Analysis Insulin Type 2 Diabetes PPT | NDEI
A1C Reduction GLP-1 RAs & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Similar A1C Goal Achievement GLP-1 RA & Glargine DURATION-3 & LEAD-5 | NDEI
Weight Loss With GLP-1 RA & Increase With Glargine in DURATION-3 & LEAD-5 | NDEI
Hypoglycemia With GLP-1 RA & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Combination GLP-1 RA & Basal Insulin Treatment Type 2 Diabetes | NDEI
Hypoglycemia & Weight After Treatment With GLP-1 RA + Basal Insulin | NDEI
Endocrine Society Obesity Guidelines Treating Type 2 Diabetes PPT | NDEI
Incretins Therapies & Heart Failure Risk in Type 2 Diabetes PPT | NDEI
No Increased Acute Pancreatitis Risk With Incretins Type 2 Diabetes | NDEI
SCALE Obesity & Prediabetes Trial Liraglutide GLP-1 Design PPT | NDEI
ELIXA No Cardiovascular Risks Lixisenatide GLP-1 CV Safety | NDEI
ELIXA Cardiovascular Safety Outcomes for Lixisenatide GLP-1 | NDEI
Diabetes Medications & Weight AHA ADA CVD Prevention Guidelines | NDEI
Type 2 Diabetes Treatment Algorithm ADA Guidelines 2016 | NDEI PPT
Strategies for Insulin Use in Type 2 Diabetes ADA Guidelines | NDEI PPT
ADA Diabetes Guidelines Pharmacologic Therapy for Older Adults | NDEI
LEADER Design Cardiovascular Safety Study Liraglutide CVOT PPT | NDEI
Liraglutide Reduced CV Events in LEADER CV Outcomes Trial PPT | NDEI
Liraglutide Reduced CV & All-Cause Death LEADER CV Outcomes Trial | NDEI
Liraglutide Cardiovascular Outcomes Trial LEADER Heart Failure PPT | NDEI
Liraglutide Reduces Microvascular Events LEADER CVOT Diabetes PPT | NDEI
LEADER Cardiovascular Safety of Liraglutide CVOT PPT | NDEI
Metabolic Surgery Postoperative Follow-Up for Type 2 Diabetes Guidelines | NDEI